Orphan drugs are medications developed for rare diseases, including certain types of cancer. Regulatory agencies offer incentives like market exclusivity, tax credits, and grant funding to encourage the development of these drugs. This is crucial for rare cancers where traditional market dynamics might not support the high costs of development.
